Drugs / roxithromycin
roxithromycin
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03148444 | Jun 2017 → Jun 2019 | primary bacterial infectious disease | Kaplan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00439062 | Jun 2006 | rheumatoid arthritis | Nazilli State Hospital | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT03414918 | Mar 2018 → Jan 2019 | hyperaldosteronism | University Hospital Padova | Unknown | No outcome recorded |
| — | NCT00197379 | May 2005 → Jan 2007 | alopecia | Hamamatsu University | Unknown | No outcome recorded |
| — | NCT00621387 | Nov 1993 → Jun 1998 | reactive arthritis | University of Helsinki | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04122040 Comparator | Mar → Sep 2011 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02819570 Background | Nov 2015 → Dec 2017 | preterm premature rupture of the membranes | Western Galilee Hospital-Nahariya | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | roxithromycin | “enteral clarithromycin or roxithromycin may be substituted” NCT02735707 ↗7“single oral dose of 150 mg of roxithromycin” NCT03414918 ↗ |
| Known as | Roxithomycin | “Roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects.” NCT00197379 ↗ |
| Known as | roxitromycin | “For example, roxitromycin inhibits T cell responces to mitogens and production of cytokines, IL-2 and IL-5.” NCT00197379 ↗ |
| Action | Inhibit | “roxitromycin inhibits T cell responces to mitogens and production of cytokines, IL-2 and IL-5.” NCT00197379 ↗ |
| Modality | Small molecule | “Roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects.” NCT00197379 ↗ |
| Route | Oral | “once-daily oral roxithromycin 300 mg” NCT00439062 ↗ |